Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion
Personalis Inc PSNL
$16.46
▼ -0.66%
($-0.11)
🎢 High Beta
Open
$16.74
Prev Close
$16.57
Day Range
$16.38 – $16.77
52W Range
$4.96 – $18.89
Market Cap
$1.76B
Beta
2.41
EPS (TTM)
$-1.09
📋 Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-06-20 |
| Shares Out. | 106,750,000 |
| Website | personalis.com/ ↗ |
| Phone | 13025310855 |
| Employees | 260 |
| Revenue | $22.4M |
| Gross Profit | $4.7M |
| Net Income | -$31.7M |
| Free Cash Flow | -$101.0M |
| Total Assets | $312.1M |
| Total Liabilities | $77.0M |
| Equity | $235.2M |
About Personalis Inc
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Personalis Inc is a publicly traded company under the ticker symbol PSNL on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-09-01)